Streetbeat News

Stock Prices

LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced positive results from a post hoc analysis of the SCORED trial, showing early clinical benefits of INPEFA (sotagliflozin) in reducing heart failure and major adverse cardiovascular events (MACE) risks. The analysis, presented at the AHA Scientific Sessions 2023, indicated significant risk reductions as early as three months after treatment. INPEFA was approved by the FDA on May 26, 2023, for reducing cardiovascular risks in adults with heart failure or type 2 diabetes with additional risk factors.

Portfolio Pulse from Benzinga Newsdesk

November 12, 2023 | 10:16 pm

SPIR

Spire Global, Inc. (NYSE:SPIR) successfully launched 11 satellites on SpaceX's Transporter-9 mission, including 10 for Space Services customers and 1 for its own data and analytics solutions. The satellites will serve Earth observation, connectivity, and RF intelligence missions across various frequency bands. Customers include GHGSat with CO2 and methane monitoring payloads, HiSky with a satellite for its Smartellite™ network, Jacobs with RF signal detection systems, and SNC with a constellation for national security. Spire's LEMUR 2 NANAZ will track NGSO broadband internet constellations. The customer satellites were manifested through an agreement with Exolaunch, which includes access to Transporter missions and the EXOpod Nova deployer.

Portfolio Pulse from Benzinga Newsdesk

November 12, 2023 | 10:12 pm

VCR

XRT

Finance experts are advising consumers to save during the holiday season due to high inflation and interest rates. Savings accounts, CDs, and bonds are offering returns up to 5%, making spending less attractive. High credit card rates, which can approach 30%, also discourage spending. The Wall Street Journal suggests reviewing past expenses and setting spending limits with family to avoid overspending. Visa Inc. (V), Mastercard Inc. (MA), SPDR S&P Retail ETF (XRT), and Vanguard Consumer Discretionary ETF (VCR) are stocks and ETFs to watch as they are impacted by consumer spending and credit usage.

Portfolio Pulse from Bibhu Pattnaik

November 12, 2023 | 10:04 pm

DDC

SGN

SHIM

DDC Enterprise Limited (NYSE:DDC), Signing Day Sports, Inc. (NYSE:SGN), and Shimmick Corporation (NASDAQ:SHIM) are set to go public this week with their IPOs. DDC is offering 4.25 million shares at $10.50 each, SGN is offering 1.5 million shares at $5.00 each, and SHIM is offering 4.55 million shares at $11.00 each. All three companies have set a 180-day insider lock-up period post-IPO.

Portfolio Pulse from Benzinga Insights

November 12, 2023 | 7:17 pm

TSLA

Tesla, Inc. (NASDAQ:TSLA) has updated its 'Motor Vehicle Order Agreement' for the Cybertruck, including a clause that prohibits buyers from reselling the vehicle within the first year of purchase. If a buyer breaches this provision, Tesla may seek $50,000 in liquidated damages or the sale value, whichever is greater. The company may also refuse to sell any future Tesla EVs to the user. This move has sparked mixed reactions on social media, with some supporting the decision to prevent flipping for profit, while others question the enforceability of the agreement. The Cybertruck is expected to significantly boost Tesla's sales volume and have a halo effect on other models, despite Elon Musk's caution about the ramp-up difficulty.

Portfolio Pulse from Shanthi Rexaline

November 12, 2023 | 4:47 pm

BLK

DOGEUSD

ETHUSD

Cryptocurrency analysts predict surges in Dogecoin and Ethereum, with Dogecoin potentially increasing by 140-170% and Ethereum aiming to break resistance at $1,900. Bitcoin's price is rallying, surpassing $35,000, fueled by interest in Bitcoin Spot ETFs and the upcoming halving event. BlackRock is optimistic about SEC approval for its Bitcoin ETF by January 2024, which could inject $200 billion into Bitcoin markets and drive the price to $330,000.

Portfolio Pulse from Benzinga Neuro

November 12, 2023 | 4:01 pm

AAPL

GOOGL

MSFT

Apple Inc. (AAPL) has been highlighted in several key tech developments, including leading the AI race according to Morgan Stanley, potential in-house battery development for iPhones post-2025, a delay in its self-driving car project, and a new macOS feature to curb warranty fraud. Google (GOOGL) is appealing to EU regulators to make Apple's iMessage compatible with other services, while Microsoft (MSFT) is also mentioned as a competitor in AI.

Portfolio Pulse from Benzinga Neuro

November 12, 2023 | 4:00 pm

BRK

TSLA

Elon Musk, CEO of Tesla, Inc., humorously remarked on Warren Buffett's missed opportunity to invest in Tesla when it was valued at just 0.1% of its current value. Musk's comment was in response to a post praising Buffett's investment wisdom. Despite Buffett's value investing strategy, which contrasts with Tesla's growth stock profile, Musk had previously suggested Tesla as an investment to Buffett's team. Buffett and his business partner Charlie Munger have recently acknowledged Musk's talent, despite earlier skepticism about Tesla's prospects.

Portfolio Pulse from Shanthi Rexaline

November 12, 2023 | 3:18 pm

FRC

KBE

KRE

SBNY

US banks are facing $650 billion in unrealized losses on bond investments due to interest rate hikes. Banks invested in low-yield Treasury bonds before the hikes, and now the value of these bonds has plummeted. The failures of Silicon Valley Bank, First Republic Bank (FRC), and Signature Bank (SBNY) were partly due to such losses. Banks are considering holding the debt until maturity or selling it to invest in higher-yielding bonds. The banking sector is under pressure, with ETFs like SPDR S&P Bank ETF (KBE) and SPDR S&P Regional Bank ETF (KRE) seeing declines.

Portfolio Pulse from Bibhu Pattnaik

November 12, 2023 | 2:46 pm

LLY

NVO

Novo Nordisk's (NYSE:NVO) weight loss drug Wegovy has been shown in a clinical trial to significantly reduce the risk of serious heart complications by 20% in obese individuals without diabetes. The Select study's results could lead to broader insurance coverage and increased usage of Wegovy, potentially maintaining Novo Nordisk's lead over Eli Lilly (NYSE:LLY), whose weight-loss drug Zepbound was recently approved in the U.S. Despite some participants discontinuing Wegovy due to gastrointestinal issues, the drug also showed a 73% reduction in progression to diabetes.

Portfolio Pulse from Benzinga Neuro

November 11, 2023 | 9:34 pm